Factor XIII deficiency diagnosis: Challenges and tools

M. Karimi, F. Peyvandi, M. Naderi, A. Shapiro

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Factor XIII deficiency (FXIIID) is a rare hereditary bleeding disorder arising from heterogeneous mutations, which can lead to life-threatening hemorrhage. The diagnosis of FXIIID is challenging due to normal standard coagulation assays requiring specific FXIII assays for diagnosis, which is especially difficult in developing countries. This report presents an overview of FXIIID diagnosis and laboratory methods and suggests an algorithm to improve diagnostic efficiency and prevent missed or delayed FXIIID diagnosis. Assays measuring FXIII activity: The currently available assays utilized to diagnose FXIIID, including an overview of their complexity, reliability, sensitivity, and specificity, as well as mutational analysis are reviewed. The use of a FXIII inhibitor assay is described. Diagnostic tools in FXIIID: Many laboratories are not equipped with quantitative FXIII activity assays, and if available, limitations in lower activity ranges are important to consider. Clot solubility tests are not standardized, have a low sensitivity, and are therefore not recommended as routine screening test; however, they are the first screening test in almost all coagulation laboratories in developing countries. To minimize the number of patients with undiagnosed FXIIID, test quality should be improved in less well-equipped laboratories. Common country-specific mutations may facilitate diagnosis through targeted genetic analysis in reference laboratories in suspected cases. However, genetic analysis may not be feasible in every country and may miss spontaneous mutations. Centralized FXIII activity measurements should also be considered. An algorithm for diagnosis of FXIIID including different approaches dependent upon laboratory capability is proposed.

Original languageEnglish
Pages (from-to)3-11
JournalInternational Journal of Laboratory Hematology
Volume40
Issue number1
DOIs
Publication statusPublished - 2018

Fingerprint

Factor XIII Deficiency
Factor XIII
Assays
Coagulation
Developing countries
Mutation
Developing Countries
Screening
Hemorrhage
Clinical Laboratory Techniques
Solubility
Sensitivity and Specificity

Keywords

  • Factor XIII
  • Factor XIII deficiency
  • Factor XIII deficiency diagnosis
  • FXIII assays
  • Laboratory assays

ASJC Scopus subject areas

  • Hematology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Factor XIII deficiency diagnosis : Challenges and tools. / Karimi, M.; Peyvandi, F.; Naderi, M.; Shapiro, A.

In: International Journal of Laboratory Hematology, Vol. 40, No. 1, 2018, p. 3-11.

Research output: Contribution to journalArticle

Karimi, M. ; Peyvandi, F. ; Naderi, M. ; Shapiro, A. / Factor XIII deficiency diagnosis : Challenges and tools. In: International Journal of Laboratory Hematology. 2018 ; Vol. 40, No. 1. pp. 3-11.
@article{15bac268426a49b59b4696d914597a13,
title = "Factor XIII deficiency diagnosis: Challenges and tools",
abstract = "Factor XIII deficiency (FXIIID) is a rare hereditary bleeding disorder arising from heterogeneous mutations, which can lead to life-threatening hemorrhage. The diagnosis of FXIIID is challenging due to normal standard coagulation assays requiring specific FXIII assays for diagnosis, which is especially difficult in developing countries. This report presents an overview of FXIIID diagnosis and laboratory methods and suggests an algorithm to improve diagnostic efficiency and prevent missed or delayed FXIIID diagnosis. Assays measuring FXIII activity: The currently available assays utilized to diagnose FXIIID, including an overview of their complexity, reliability, sensitivity, and specificity, as well as mutational analysis are reviewed. The use of a FXIII inhibitor assay is described. Diagnostic tools in FXIIID: Many laboratories are not equipped with quantitative FXIII activity assays, and if available, limitations in lower activity ranges are important to consider. Clot solubility tests are not standardized, have a low sensitivity, and are therefore not recommended as routine screening test; however, they are the first screening test in almost all coagulation laboratories in developing countries. To minimize the number of patients with undiagnosed FXIIID, test quality should be improved in less well-equipped laboratories. Common country-specific mutations may facilitate diagnosis through targeted genetic analysis in reference laboratories in suspected cases. However, genetic analysis may not be feasible in every country and may miss spontaneous mutations. Centralized FXIII activity measurements should also be considered. An algorithm for diagnosis of FXIIID including different approaches dependent upon laboratory capability is proposed.",
keywords = "Factor XIII, Factor XIII deficiency, Factor XIII deficiency diagnosis, FXIII assays, Laboratory assays",
author = "M. Karimi and F. Peyvandi and M. Naderi and A. Shapiro",
year = "2018",
doi = "10.1111/ijlh.12756",
language = "English",
volume = "40",
pages = "3--11",
journal = "International Journal of Laboratory Hematology",
issn = "1751-5521",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Factor XIII deficiency diagnosis

T2 - Challenges and tools

AU - Karimi, M.

AU - Peyvandi, F.

AU - Naderi, M.

AU - Shapiro, A.

PY - 2018

Y1 - 2018

N2 - Factor XIII deficiency (FXIIID) is a rare hereditary bleeding disorder arising from heterogeneous mutations, which can lead to life-threatening hemorrhage. The diagnosis of FXIIID is challenging due to normal standard coagulation assays requiring specific FXIII assays for diagnosis, which is especially difficult in developing countries. This report presents an overview of FXIIID diagnosis and laboratory methods and suggests an algorithm to improve diagnostic efficiency and prevent missed or delayed FXIIID diagnosis. Assays measuring FXIII activity: The currently available assays utilized to diagnose FXIIID, including an overview of their complexity, reliability, sensitivity, and specificity, as well as mutational analysis are reviewed. The use of a FXIII inhibitor assay is described. Diagnostic tools in FXIIID: Many laboratories are not equipped with quantitative FXIII activity assays, and if available, limitations in lower activity ranges are important to consider. Clot solubility tests are not standardized, have a low sensitivity, and are therefore not recommended as routine screening test; however, they are the first screening test in almost all coagulation laboratories in developing countries. To minimize the number of patients with undiagnosed FXIIID, test quality should be improved in less well-equipped laboratories. Common country-specific mutations may facilitate diagnosis through targeted genetic analysis in reference laboratories in suspected cases. However, genetic analysis may not be feasible in every country and may miss spontaneous mutations. Centralized FXIII activity measurements should also be considered. An algorithm for diagnosis of FXIIID including different approaches dependent upon laboratory capability is proposed.

AB - Factor XIII deficiency (FXIIID) is a rare hereditary bleeding disorder arising from heterogeneous mutations, which can lead to life-threatening hemorrhage. The diagnosis of FXIIID is challenging due to normal standard coagulation assays requiring specific FXIII assays for diagnosis, which is especially difficult in developing countries. This report presents an overview of FXIIID diagnosis and laboratory methods and suggests an algorithm to improve diagnostic efficiency and prevent missed or delayed FXIIID diagnosis. Assays measuring FXIII activity: The currently available assays utilized to diagnose FXIIID, including an overview of their complexity, reliability, sensitivity, and specificity, as well as mutational analysis are reviewed. The use of a FXIII inhibitor assay is described. Diagnostic tools in FXIIID: Many laboratories are not equipped with quantitative FXIII activity assays, and if available, limitations in lower activity ranges are important to consider. Clot solubility tests are not standardized, have a low sensitivity, and are therefore not recommended as routine screening test; however, they are the first screening test in almost all coagulation laboratories in developing countries. To minimize the number of patients with undiagnosed FXIIID, test quality should be improved in less well-equipped laboratories. Common country-specific mutations may facilitate diagnosis through targeted genetic analysis in reference laboratories in suspected cases. However, genetic analysis may not be feasible in every country and may miss spontaneous mutations. Centralized FXIII activity measurements should also be considered. An algorithm for diagnosis of FXIIID including different approaches dependent upon laboratory capability is proposed.

KW - Factor XIII

KW - Factor XIII deficiency

KW - Factor XIII deficiency diagnosis

KW - FXIII assays

KW - Laboratory assays

UR - http://www.scopus.com/inward/record.url?scp=85031319597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031319597&partnerID=8YFLogxK

U2 - 10.1111/ijlh.12756

DO - 10.1111/ijlh.12756

M3 - Article

AN - SCOPUS:85031319597

VL - 40

SP - 3

EP - 11

JO - International Journal of Laboratory Hematology

JF - International Journal of Laboratory Hematology

SN - 1751-5521

IS - 1

ER -